# US 2016/0354388 A1 · Respirable Agglomerates of Porous Carrier Particles and Micronized Drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354388 A1
- Document ID: US20160354388A1
- Status: Published application
- Kind: A1
- Application number: 15/238,842
- Filed: 2016-08-17
- Published: 2016-12-08
- Earliest claimed: 2013-03-14
- Assignees: Novartis AG
- Inventors: Michael Hartman; Thomas E. Tarara; Patrick Teung; Jeffry G. Weers
- Web page: https://patentgrep.com/patent/US20160354388A1

## CPC

- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/145: {with organic compounds}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1682: {Processes}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4704: 2-Quinolinones, e.g. carbostyril
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the present invention provide a dry powder composition comprising porous carrier particles associated with one, two, three or more micronized drugs or APIs wherein an ordered mixture between the micronized drug or drugs and the carrier particle results, such that the micronized drug or drugs adhere strongly to the carrier particles forming a stable ordered mixture of respirable agglomerates. Embodiments of the present invention further comprise a spray-drying process to create the respirable agglomerates. Embodiments of the present invention further relate to the use of the dry powder formulation comprising respirable agglomerates for the treatment of a patient having a disease or condition which is treatable thereby.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

A process for making a dry powder formulation of respirable agglomerate particles, the process comprising the steps of:
(a) preparing a first feedstock comprising a hydrophobic excipient dispersed in an aqueous liquid phase and spray-drying said first feedstock to provide a bulk powder composition comprising a plurality of small porous powder carrier particles;
(b) providing at least a first active drug ingredient to having a size of at least 50% having a geometric diameter of less than 3 microns;
(c) preparing a second feedstock comprising a suspension of the carrier particles of step (a) and the drug particles of step (b) in a non-aqueous anti-solvent; and
(d) subjecting the second feedstock to a solvent removal process to yield a bulk powder formulation comprising an ordered mixture of respirable aggregate particles comprising small porous carrier particles and micronized drug particles, wherein the respirable agglomerate particles are characterized by a tapped density of 0.03 to 0.5 g/cm3, and a FPF<4.7 μm of at least about 50%.

### Claim 19 (depends on 18)

The process of claim 18 wherein the hydrophobic excipient comprises DSPC and calcium chloride.

### Claim 20 (depends on 19)

The process of claim 19 wherein the first active comprises a beta adrenoreceptor agonist, and the second active comprises an anti-inflammatory.

### Claim 21 (depends on 20)

The process of claim 20 wherein the beta adrenoreceptor agonist comprises indacaterol, and the anti-inflammatory comprises mometasone.

### Claim 22 (depends on 21)

The process of claim 21 and further including a third active.

### Claim 23 (depends on 22)

The process of claim 22 wherein the third active comprises a glycopyrrolate.

### Claim 24

(canceled)

### Claim 25

(canceled)
